In 2025, around 70–75% of all drug trials (Phases I–IV) worldwide will be managed end-to-end by CROs under full‑service outsourcing (FSO) agreements—not just task‑based (FSP) support. That amounts to nearly three out of every four trials being fully entrusted to CRO …
Read More
